Hubei Biocause Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 000627.SZ

Hubei Biocause Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -27.67

Hubei Biocause Pharmaceutical Co., Ltd. Price to Earnings Ratio (P/E) is -27.67 on January 14, 2025, a -34.58% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Hubei Biocause Pharmaceutical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -12.13 on July 10, 2024, which is 56.17% above the current Price to Earnings Ratio (P/E).
Hubei Biocause Pharmaceutical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -38.74 on December 16, 2024, which is -40.04% below the current Price to Earnings Ratio (P/E).
Hubei Biocause Pharmaceutical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -20.87.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shenzhen Stock Exchange: 000627.SZ

Hubei Biocause Pharmaceutical Co., Ltd.

CEO	Ms. Wenxia Zhou
IPO Date	Nov. 12, 1996
Location	China
Headquarters	#122 Yangwan Road
Employees	1,765
Sector	Health Care
Industries Pharmaceuticals

Description

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China.

Key trends

Past 5 years